Don’t miss out on important information!
Keep up to date with the latest announcements from official health organisations, such as NICE the EMA or the MHRA.
Have a look at some of this week’s updates and Register for a full review
Dear Viewers,
National Institute for Health and Clinical Excellence
NICE has issued final guidance on ranibizumab (Lucentis, Novartis) for the treatment of diabetic macular oedema. It has concluded that the drug does not represent an effective use of NHS resources and has therefore not recommended its use for this condition.
To read more on this article click here >>
NICE has published final draft guidance recommending the use of apixaban (Eliquis, Bristol-Myers Squibb and Pfizer) as an option for the prevention of venous thromboembolism in adults who have undergone planned total hip replacement or total knee replacement surgery.
To read more on this article click here >>
Medicines and Healthcare products Regulatory Agency
The MHRA has warned that the blood glucose analyser Glucose 201+, manufactured by HemoCue AB, may miss hyperglycaemia if used with outdated software (version 106 or lower). This is of particular concern in neonates.
To read more on this article click here >>
The MHRA has launched a learning module on selective serotonin reuptake inhibitors (SSRI) antidepressants for doctors, pharmacists and nurses involved in the care of patients with depression. This self-directed learning package outlines the key risks of this important class of medicines.
To read more on this article click here >>
Department of Health
November GP and Practice Team Bulletin published
To read more on this article click here >>